Efficacy and Safety of Relugolix in Advanced Prostate Cancer: Subgroup Analysis of Concomitant Therapies from the HERO Study

Background: In the phase 3 HERO study, the oral GnRH receptor antagonist, relugolix, demonstrated suppression of testosterone to castrate levels in 96.7% of patients, which was superior to leuprolide, and a 54% lower risk of major adverse cardiovascu...